|
2020 Conference Publication Evaluation of Minimal Residual Disease (MRD) Negativity in Patients with Relapsed or Refractory Multiple Myeloma Treated in the Candor StudyLandgren, Ola, Weisel, Katja, Dachs, Laura Rosinol, Moreau, Philippe, Turgut, Mehmet, Hajek, Roman, Mollee, Peter, Kim, Jin Seok, Zhang, Jianqi, Go, Ning, Morris, Christopher L. and Usmani, Saad Z. (2020). Evaluation of Minimal Residual Disease (MRD) Negativity in Patients with Relapsed or Refractory Multiple Myeloma Treated in the Candor Study. 62nd Annual Meeting of the American-Society-of-Hematology (ASH), Electr Network, Dec 05-08, 2020. AMSTERDAM: ELSEVIER. doi: 10.1182/blood-2020-141291 |
|
2020 Conference Publication The role of whole body STIR MRI in assessing first biochemical relapse in patients with myelomaRowland, James and Mollee, Peter (2020). The role of whole body STIR MRI in assessing first biochemical relapse in patients with myeloma. 62nd ASH Annual Meeting, Online, 5-8 December 2020. Washington, DC United States: American Society of Hematology. doi: 10.1182/blood-2020-139194 |
|
2020 Conference Publication A cost-effectiveness analysis of front-line treatment strategies in early stage follicular lymphomaTobin, Joshua W.D., Hapgood, Greg, Gandhi, Maher K., Mollee, Peter, Ma, Ti, Crothers, Anna and Scuffham, Paul (2020). A cost-effectiveness analysis of front-line treatment strategies in early stage follicular lymphoma. 62nd ASH Annual Meeting and Exposition, Online, 5-8 December 2020. Washington, DC USA: American Society of Hematology. doi: 10.1182/blood-2020-138590 |
|
2020 Conference Publication Health-Related Quality of Life in Patients with AL Amyloidosis Treated with Daratumumab, Bortezomib, Cyclophosphamide, and Dexamethasone: Results from the Phase 3 Andromeda StudySanchorawala, Vaishali, Palladini, Giovanni, Minnema, Monique C., Jaccard, Arnaud, Lee, Hans C., Gibbs, Simon D., Mollee, Peter, Venner, Christopher P., Lu, Jin, Schonland, Stefan, Gatt, Moshe, Suzuki, Kenshi, Kim, Kihyun, Cibeira, M. Teresa, Beksac, Meral, Libby, Edward, Valent, Jason, Hungria, Vania T. M., Wong, Sandy W., Rosenzweig, Michael, Bumma, Naresh, Chauveau, Dominique, Gries, Katharine S., Fastenau, John, NamPhuong Tran, , Qin, Xiang, Vasey, Sandra Y., Tromp, Brenda, Weiss, Brendan M. ... Wechalekar, Ashutosh D. (2020). Health-Related Quality of Life in Patients with AL Amyloidosis Treated with Daratumumab, Bortezomib, Cyclophosphamide, and Dexamethasone: Results from the Phase 3 Andromeda Study. 62nd Annual Meeting of the American-Society-of-Hematology (ASH), Electr Network, Dec 05-08, 2020. AMSTERDAM: ELSEVIER. doi: 10.1182/blood-2020-139438 |
|
2020 Conference Publication The use of monocyte subset repartitioning by flow cytometry for diagnosis of chronic myelomonocytic leukemiaMurali, Aarya, Cross, Donna and Mollee, Peter (2020). The use of monocyte subset repartitioning by flow cytometry for diagnosis of chronic myelomonocytic leukemia. 62nd ASH Annual Meeting and Exposition, Online, 5-8 December 2020. AMSTERDAM: American Society of Hematology. doi: 10.1182/blood-2020-140966 |
|
2020 Conference Publication Reduction in Absolute Involved Free Light Chain and Difference between Involved and Uninvolved Free Light Chain Is Associated with Prolonged Major Organ Deterioration Progression-Free Survival in Patients with Newly Diagnosed AL Amyloidosis Receiving Bortezomib, Cyclophosphamide, and Dexamethasone with or without Daratumumab: Results from AndromedaComenzo, Raymond L., Kastritis, Efstathios, Palladini, Giovanni, Minnema, Monique C., Wechalekar, Ashutosh D., Jaccard, Arnaud, Sanchorawala, Vaishali, Lee, Hans C., Gibbs, Simon D., Mollee, Peter, Venner, Christopher P., Lu, Jin, Schonland, Stefan, Gatt, Moshe, Suzuki, Kenshi, Kim, Kihyun, Cibeira, M. Teresa, Beksac, Meral, Libby, Edward, Valent, Jason, Hungria, Vania T. M., Wong, Sandy W., Rosenzweig, Michael, Bumma, Naresh, Chauveau, Dominique, Dimopoulos, Meletios A., NamPhuong Tran, , Qin, Xiang, Vasey, Sandra Y. ... Merlini, Giampaolo (2020). Reduction in Absolute Involved Free Light Chain and Difference between Involved and Uninvolved Free Light Chain Is Associated with Prolonged Major Organ Deterioration Progression-Free Survival in Patients with Newly Diagnosed AL Amyloidosis Receiving Bortezomib, Cyclophosphamide, and Dexamethasone with or without Daratumumab: Results from Andromeda. 62nd Annual Meeting of the American-Society-of-Hematology (ASH), Electr Network, Dec 05-08, 2020. AMSTERDAM: ELSEVIER. doi: 10.1182/blood-2020-137582 |
|
2020 Conference Publication Carfilzomib, Dexamethasone, and Daratumumab Versus Carfilzomib and Dexamethasone in Relapsed or Refractory Multiple Myeloma: Subgroup Analysis of the Phase 3 Candor Study in Patients with Early or Late RelapseWeisel, Katja, Geils, George F., Karlin, Lionel, Mollee, Peter, Chung, Tae-Hoon, Min, Chang-Ki, Sunami, Kazutaka, Goldrick, Amanda, Fang, Belle, Fowler, Jessica and Mateos, Maria-Victoria (2020). Carfilzomib, Dexamethasone, and Daratumumab Versus Carfilzomib and Dexamethasone in Relapsed or Refractory Multiple Myeloma: Subgroup Analysis of the Phase 3 Candor Study in Patients with Early or Late Relapse. 62nd Annual Meeting of the American-Society-of-Hematology (ASH), Electr Network, Dec 05-08, 2020. AMSTERDAM: ELSEVIER. doi: 10.1182/blood-2020-133908 |
|
2020 Conference Publication The Impact of S-Li-M Criteria in Myeloma in a Real-Life Population: Patient & Disease Characteristics, Treatment and Outcomes from the Australian and New Zealand Myeloma and Related Diseases Registry (MRDR)Ho, Phoebe Joy, Moore, Elizabeth M., Wellard, Cameron, Quach, Hang, Blacklock, Hilary, Harrison, Simon J., McDonald, Emma-Jane, McQuilten, Zoe, Wood, Erica M., Mollee, Peter and Spencer, Andrew (2020). The Impact of S-Li-M Criteria in Myeloma in a Real-Life Population: Patient & Disease Characteristics, Treatment and Outcomes from the Australian and New Zealand Myeloma and Related Diseases Registry (MRDR). 62nd Annual Meeting of the American-Society-of-Hematology (ASH), Electr Network, Dec 05-08, 2020. AMSTERDAM: ELSEVIER. doi: 10.1182/blood-2020-141511 |
|
2020 Conference Publication An individualised, supervised exercise program is safe and feasible for patients with multiple myeloma: The MyeEx StudyNicol, Jennifer L., Hill, Michelle M., Cunningham, Brent, Nunan, Elizabeth, Woodrow, Carmel, Keating, Eliza, Adlard, Kirsten, Smith, Michelle, Mollee, Peter, Weber, Nicholas, Nicol, Andrew J. and Skinner, Tina L. (2020). An individualised, supervised exercise program is safe and feasible for patients with multiple myeloma: The MyeEx Study. COSA's 47th Annual Scientific Meeting, Quality and Safety, Implementation Science, Cardio-Oncology, Virtual, 11–13 November 2020. Chichester, West Sussex, United Kingdom: Wiley-Blackwell. doi: 10.1111/ajco.13499 |
|
2020 Conference Publication 99Tc-DPD Bone scintigraphy correlates with left ventricular wall thickness and global longitudinal strain in patients with ATTR wild type cardiac amyloidosisRobinson, J., Burrage, M., Ngai, S., Mackenzie, E., Duong, J., Mollee, P. and Korczyk, D. (2020). 99Tc-DPD Bone scintigraphy correlates with left ventricular wall thickness and global longitudinal strain in patients with ATTR wild type cardiac amyloidosis. 68th Cardiac Society of Australia and New Zealand Annual Scientific Meeting, the International Society for Heart Research Australasian Section Annual Scientific Meeting and the 14th Annual Australia and New Zealand Endovascular Therapies Meeting, Online, 11-13 December 2020. Chatswood, NSW Australia: Elsevier. doi: 10.1016/j.hlc.2020.09.069 |
|
2020 Conference Publication Changing picture of ATTR wild type cardiomyopathy in Australia – Queensland Amyloidosis Centre experienceKorczyk, D., Woodcroft-Brown, V., Maffey, M. and Mollee, P. (2020). Changing picture of ATTR wild type cardiomyopathy in Australia – Queensland Amyloidosis Centre experience. 68th Cardiac Society of Australia and New Zealand Annual Scientific Meeting, the International Society for Heart Research Australasian Section Annual Scientific Meeting and the 14th Annual Australia and New Zealand Endovascular Therapies Meeting, Online, 11-13 December 2020. Chatswood, NSW Australia: Elsevier. doi: 10.1016/j.hlc.2020.09.100 |
|
2019 Conference Publication Identification of Novel Immune Cell Populations in Lenalidomide Refractory Relapsed Multiple Myeloma Patients Treated with Pomalidomide and Low Dose DexamethasoneKalff, Anna, Khong, Tiffany, Ramachandran, Malarmathy, Norton, Sam, Mitchell, Andrew, Reynolds, John, Quach, Hang, Ho, P. Joy, Horvath, Noemi, Mollee, Peter, Kennedy, Nola, Kemp, Roslyn and Spencer, Andrew (2019). Identification of Novel Immune Cell Populations in Lenalidomide Refractory Relapsed Multiple Myeloma Patients Treated with Pomalidomide and Low Dose Dexamethasone. 61st Annual Meeting and Exposition of the American-Society-of-Hematology (ASH), Orlando Fl, Dec 05-10, 2019. AMSTERDAM: ELSEVIER. doi: 10.1182/blood-2019-130154 |
|
2019 Conference Publication Real-World Outcome for Newly Diagnosed Patients with Functional High-Risk Myeloma - a Myeloma and Related Diseases Registry AnalysisSpencer, Andrew, Mollee, Peter, Blacklock, Hilary Anne, Harrison, Simon, Quach, Hang, Ho, P. Joy, Spearing, Ruth, Hocking, Jay, Augustson, Bradley, Prince, H. Miles, Moore, Elizabeth M., McQuilten, Zoe, Wood, Erica M. and Wellard, Cameron (2019). Real-World Outcome for Newly Diagnosed Patients with Functional High-Risk Myeloma - a Myeloma and Related Diseases Registry Analysis. 61st Annual Meeting and Exposition of the American-Society-of-Hematology (ASH), Orlando Fl, Dec 05-10, 2019. AMSTERDAM: ELSEVIER. doi: 10.1182/blood-2019-129431 |
|
2019 Conference Publication Daratumumab, lenalidomide, and dexamethasone (d-rd) delivers a reduction and delay in worsening of pain symptoms for patients with newly diagnosed multiple myeloma ineligible for transplantGries, Katharine, Facon, Thierry, Plesner, Torben, Usmani, Saad, Kumar, Shaji, Orlowski, Robert Z., Bahlis, Nizar J., Nahi, Hareth, Mollee, Peter, Ramasamy, Karthik, Roussel, Murielle, Delforge, Michel, Karlin, Lionel, Arnulf, Bertrand, Chari, Ajai, Hulin, Cyrille, Weisel, Katja, He, Jianming, Ho, Kai Fai, Wang, Jim, Van Rampelbergh, Rian, Uhlar, Clarissa, Kobos, Rachel and Perrot, Aurore (2019). Daratumumab, lenalidomide, and dexamethasone (d-rd) delivers a reduction and delay in worsening of pain symptoms for patients with newly diagnosed multiple myeloma ineligible for transplant. 17th International Myeloma Workshop, Boston, MA, 12-15 September 2019. Dallas: CIG Media Group. doi: 10.1016/j.clml.2019.09.375 |
|
2019 Conference Publication Receiving four or less cycles of therapy predicts poor survival in newly diagnosed transplant ineligible patients with myeloma who are treated with bortezomib-based inductionMollee, Peter, Boyle, Stephen, Wellard, Cameron, Moore, Elizabeth, Blacklock, Hilary, Harrison, Simon J., Ho, P. Joy, Hocking, Jay, McQuilten, Zoe, Quach, Hang, Spearing, Ruth, Wood, Erica and Spencer, Andrew (2019). Receiving four or less cycles of therapy predicts poor survival in newly diagnosed transplant ineligible patients with myeloma who are treated with bortezomib-based induction. 17th International Myeloma Workshop, Boston, MA United States, 12 - 15 September 2019. New York, NY United States: Elsevier. doi: 10.1016/j.clml.2019.09.388 |
|
2019 Conference Publication Development of an individualized, supervised exercise intervention as standard care for patients with multiple MyelomaNicol, Jennifer, Woodrow, Carmel, Burton, Nicola, Hill, Michelle, Skinner, Tina, Mollee, Peter and Nicol, Andrew (2019). Development of an individualized, supervised exercise intervention as standard care for patients with multiple Myeloma. 17th International Myeloma Workshop, Boston, MA United States, 12-15 September 2019. New York, NY United States: Elsevier . doi: 10.1016/j.clml.2019.09.355 |
|
2019 Conference Publication Significantly improved relative survival of patients with myeloma in Queensland with treatment advancesMollee, Peter, Harwood, Matthew, Dunn, Nathan, Moore, Julie and Hapgood, Greg (2019). Significantly improved relative survival of patients with myeloma in Queensland with treatment advances. 17th International Myeloma Workshop, Boston, MA, 12-15 September 2019. Dallas: CIG Media Group. doi: 10.1016/j.clml.2019.09.387 |
|
2019 Conference Publication Pacific Islanders with multiple myeloma are younger and have inferior survival when compared to other ethnicities: a study from the Australian and New Zealand Myeloma and Related Diseases Registry (MRDR)Blacklock, Hilary, Moore, Elizabeth, Wellard, Cameron, Harrison, Simon J., Ho, P. Joy, Hocking, Jay, McQuilten, Zoe, Mollee, Peter, Quach, Hang, Spearing, Ruth, Wood, Erica and Spencer, Andrew (2019). Pacific Islanders with multiple myeloma are younger and have inferior survival when compared to other ethnicities: a study from the Australian and New Zealand Myeloma and Related Diseases Registry (MRDR). 17th International Myeloma Workshop, Boston, MA, 12-15 September 2019. Dallas: CIG Media Group. doi: 10.1016/j.clml.2019.09.354 |
|
2019 Conference Publication Lysozyme amyloidosis – Two novel cases with newly described genetic mutationsMcMichael, L., Chang, S., Gibbs, S., Mollee, P., Gillmore, J., Horvath, N., Crail, S. and Jobert, A. (2019). Lysozyme amyloidosis – Two novel cases with newly described genetic mutations. ISN World Congress of Nephrology (WCN) 2024, Buenos Aires, Argentina, 13-16 April 2024. New York, NY United States: Elsevier. doi: 10.1016/j.ekir.2019.05.590 |
|
2019 Conference Publication Validation of the Boston University staging system in AL amyloidosisTomlinson, R., Matigain, N. and Mollee, P. (2019). Validation of the Boston University staging system in AL amyloidosis. 29th European Hematology Association Congress EHA24, Madrid, Spain, 13-16 June 2024. Philadelphia, PA United States: Wiley. doi: 10.1097/01.hs9.0000567024.85321.eb |
